References
- Castro DV, Zengin ZB, Malhotra J, Bergerot CD, Meza L, Dizman N, et al. Perceptions of COVID-19 vaccination in patients with genitourinary cancers: a survey study. Cancer Invest. 2022;14:1–9. doi:10.1080/07357907.2022.2136683.
- Sookaromdee P, Wiwanitkit V. Factors influencing COVID-19 vaccine acceptance and hesitancy: correspondence. Hum Vaccin Immunother. 2022;18:2085471. doi:10.1080/21645515.2022.2085471.
- Mungmunpuntipantip R, Wiwanitkit V. COVID-19 vaccination hesitancy. Recenti Prog Med. 2021;112(9):596. doi:10.1701/3658.36425.
- Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors affecting COVID-19 vaccine acceptance: an international survey among low- and middle-income countries. Vaccines (Basel). 2021;9(5):515. doi:10.3390/vaccines9050515.
- Ghazy RM, Abdou MS, Awaidy S, Sallam M, Elbarazi I, Youssef N, et al. Acceptance of COVID-19 vaccine booster doses using the health belief model: a cross-sectional study in low-middle- and high-income countries of the East Mediterranean region. Int J Environ Res Public Health. 2022;19(19):12136. doi:10.3390/ijerph191912136.
- Javadinia SA, Alizadeh K, Mojadadi MS, Nikbakht F, Dashti F, Joudi M, et al. COVID-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne). 2022;13:860238. doi:10.3389/fendo.2022.860238.
- Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2022;40(1):26–34. doi:10.1080/07357907.2021.1992420.
- Joudi M, Binabaj MM, Porouhan P, PeyroShabany B, Tabasi M, Panah DF, et al. A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere with the outcome? Front Endocrinol (Lausanne). 2022;13:798975. doi:10.3389/fendo.2022.798975.